Epizyme, Inc.

Arrakis Therapeutics, Inc.

Jennifer C Petter

Richard Chesworth

Kevin Wayne Kuntz

Lorna Helen Mitchell

Megan Alene Cloonan Foley

Carl Eric Schwartz

Gnanasambandam Kumaravel

Donovan Noel Chin

Neil Kubica

Herschel Mukherjee

Chao Fang

Jonathan Craig Blain

The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcripts that bind compounds and are thus druggable, methods of screening drug candidates, and methods of determining drug binding sites and/or accessible or reactive sites on a target RNA.

Nucleic acid-binding photoprobes and uses thereof

The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Isoxazole carboxamides as irreversible SMYD inhibitors

The present disclosure provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Growing community of inventors

Stow, MA, United States of America

Jennifer C Petter